BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TAK-505 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TAK-505\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07436728-11368@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20300818
DTEND;VALUE=DATE:20300819
SUMMARY:TAK-505: Phase 1/2 readout est. (NCT07436728)
DESCRIPTION:TAK-505\, phase 1/2.\nStudy: A Study of TAK-505 in Adults With 
 Solid Tumors\nEstimated primary completion: 18 August 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tak-505#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07436728
URL:https://assetmemo.bio/drug/tak-505#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
